Press & Media
CLERIVY is a Korean skincare brand bringing clarity to blemish care. We create hydrocolloid pimple patches for surfaced spots and microdart spot patches for early bumps—so each patch fits a different spot stage. Our name brings together CLEAR and VALIDITY through “I,” for Individual and Ingredients: individual skin needs, ingredients chosen with purpose, and product information made easier to understand. This official press room brings together verified brand, product, testing, regulatory, launch, and media facts.
Company Announcement ·
On August 25, 2026, CLERIVY launched its Hydrocolloid Pimple Patch and Microdart Spot Patch on Amazon.com for U.S. customers. Both are cosmetic products designed for different spot stages. A separate OTC Microdart Acne Patch with 2% salicylic acid is planned for October 2026 and carries its own Drug Facts labeling.
Issued by CLERIVY, a brand operated by GUHADA Co., Ltd. · Distributed via PR Newswire.
These links document third-party distribution of CLERIVY's August 25, 2026 U.S. launch announcement. The U.S. and global pages are syndicated copies of the company announcement, not independent product reviews or editorial endorsements. The Korean-language outlets published articles about the launch.
Syndicated company announcement ·
Syndicated company announcement ·
Syndicated company announcement ·
Syndicated company announcement ·
Syndicated company announcement ·
Korean-language launch article ·
구하다, 스킨케어 브랜드 ‘클레리비’ 미국 아마존 진출…OTC 패치는 10월 출시
Read CLERIVY launch coverage on Korea Daily (미주중앙일보) ↗Korean-language launch article ·
구하다, 자체 브랜드 트러블 패치 2종 미국 아마존 판매 개시
Read CLERIVY launch coverage on EToday (이투데이) ↗Korean-language launch article ·
‘검증된 성분’ 앞세웠다… 구하다, 자체 스킨케어 브랜드 미국 아마존 론칭
Read CLERIVY launch coverage on Fashionbiz (패션비즈) ↗Korean-language launch article ·
구하다, 美 트러블 케어 시장 공략…‘클레리비’ 아마존 론칭
Read CLERIVY launch coverage on MyDaily (마이데일리) ↗If you are comparing Korean pimple patches, start with the stage of the spot and the product classification. Choose the cosmetic Microdart Spot Patch for an early bump you can feel before it surfaces. Choose the cosmetic Hydrocolloid Pimple Patch for a surfaced spot on healthy, intact skin that you want to cover. The Microdart Acne Patch is a separate OTC drug for acne with its own Drug Facts label and is scheduled for October 2026.
Early bump · Cosmetic · Available now
A cosmetic two-step kit for an early bump you can feel before it surfaces. Each 13.5 mm patch has 16 water-soluble microdarts and is used with the included Blemish Clearing Pad. The formula features 7% niacinamide, 3% tranexamic acid, and a vitamin C derivative. Available in 6-, 12-, and 18-patch kits.
Surfaced spot · Cosmetic · Available now
A cosmetic hydrocolloid patch for covering a surfaced spot on healthy, intact skin. Available in 10 mm and 12 mm sizes, with 30-, 72-, and 96-count boxes. Apply to clean, completely dry skin and follow the on-pack direction: wear for 4–8 hours, or until the patch turns opaque. Contains less than 0.5% salicylic acid for cosmetic purposes only.
OTC monograph drug · Scheduled for October 2026
A separate OTC monograph drug for acne with 2% salicylic acid as its sole active ingredient. Four- and eight-patch packs are planned for U.S. release in October 2026. Follow its Drug Facts label; do not apply the cosmetic-patch directions to this product.
Compare CLERIVY hydrocolloid and microdart pimple patches by spot stage →
CLERIVY separates each patch by spot stage and product classification. The cosmetic Microdart Spot Patch is for an early bump, while the cosmetic Hydrocolloid Pimple Patch is for a surfaced spot on healthy, intact skin. The Microdart Acne Patch is a separate OTC monograph drug with its own Drug Facts labeling. FDA listing does not constitute FDA approval or endorsement of the product.
The Hydrocolloid Pimple Patch and Microdart Spot Patch each have two one-week use studies and a separate 24-hour primary skin irritation patch test. The two one-week Microdart Spot Patch studies evaluated the complete Blemish Clearing Pad and patch routine. The 24-hour tests evaluated each patch separately. These six studies do not apply to the Microdart Acne Patch.
Hydrocolloid Pimple Patch only
CUTIS Biomedical Research Center conducted a one-week sensitive-skin human use study with 23 participants (CBRC-E-260610-52). No assessed adverse skin reactions were observed.
Hydrocolloid Pimple Patch only
CUTIS Biomedical Research Center conducted a one-week non-comedogenic human use study with 22 participants (CBRC-E-260610-53). No assessed adverse skin reactions were observed.
Microdart Spot Patch only
CUTIS Biomedical Research Center conducted a one-week sensitive-skin study with 23 participants (CBRC-E-260611-54). No assessed adverse skin reactions were observed during the 1-week study.
Microdart Spot Patch only
CUTIS Biomedical Research Center conducted a one-week non-comedogenic and blemish-area study with 21 participants (CBRC-E-260611-55). No assessed adverse skin reactions were observed during the 1-week study.
Hydrocolloid Pimple Patch only
In a 24-hour primary skin irritation patch test of 31 adults (CBRC-I-260818-96-01), no irritation reactions were observed at the 1- or 24-hour assessments after removal; the mean skin reaction score was 0.00 under the report criteria.
Microdart Spot Patch only
In a 24-hour primary skin irritation patch test of 31 adults (CBRC-I-260818-96-02), no irritation reactions were observed at the 1- or 24-hour assessments after removal; the mean skin reaction score was 0.00 under the report criteria.
The two one-week Microdart Spot Patch studies evaluated the complete routine: Blemish Clearing Pad followed by Microdart Spot Patch. The separate 24-hour primary skin irritation patch tests excluded people with sensitive or hypersensitive skin. These short-term results do not mean non-irritating, hypoallergenic, or suitable for every skin type. The Hydrocolloid Pimple Patch and Microdart Spot Patch are cosmetic products; neither is intended to treat, prevent, or cure acne or any other medical condition.
Explore our brand story, compare patch formats, and find product testing, directions, and the separate OTC Drug Facts.
High-resolution originals, approved CLERIVY logo files, captions, and product fact checks are available to journalists through the Media Contact below.
CLERIVY is a Korean skincare brand bringing clarity to blemish care. We create hydrocolloid pimple patches for surfaced spots and microdart spot patches for early bumps—so each patch fits a different spot stage. Our name brings together CLEAR and VALIDITY through “I,” for Individual and Ingredients: individual skin needs, ingredients chosen with purpose, and product information made easier to understand.
CLERIVY organizes pimple patches by spot stage and product classification. Its cosmetic Microdart Spot Patch is for early bumps, its cosmetic Hydrocolloid Pimple Patch is for surfaced spots, and its Microdart Acne Patch is a separate OTC monograph drug with its own Drug Facts labeling.
CLERIVY
CLERIVY MICRODART ACNE (salicylic acid 2%) is listed with the U.S. Food and Drug Administration as an over-the-counter monograph drug under OTC Monograph M006, Topical Acne Drug Products. The 4-patch and 8-patch packs carry NDC 87934-111-04 and NDC 87934-111-08, respectively. The listing identifies GUHADA Co., Ltd. as the labeler. Its complete Drug Facts labeling is published by the U.S. National Library of Medicine under SPL Set ID 555e0963-025e-3731-e063-6394a90a679d.
Listing of a drug with FDA does not constitute FDA approval or endorsement of the product. CLERIVY Microdart Acne Patch is scheduled for U.S. release in October 2026.
CLERIVY Hydrocolloid Pimple Patch and CLERIVY Microdart Spot Patch are cosmetic products and are not drugs. Both cosmetic packages state: “This product contains less than 0.5% Salicylic Acid for cosmetic purposes only. It is not intended to treat, prevent, or cure acne or any other medical condition.”
Blemish Clearing Pads included with the Microdart Spot Patch are not intended for sanitizing or antiseptic use.
Last updated:
Press & Media
CLERIVY Press Room
CLERIVY is a Korean skincare brand bringing clarity to blemish care. We create hydrocolloid pimple patches for surfaced spots and microdart spot patches for early bumps—so each patch fits a different spot stage. Our name brings together CLEAR and VALIDITY through “I,” for Individual and Ingredients: individual skin needs, ingredients chosen with purpose, and product information made easier to understand. This official press room brings together verified brand, product, testing, regulatory, launch, and media facts.
Company Announcement ·
On August 25, 2026, CLERIVY launched its Hydrocolloid Pimple Patch and Microdart Spot Patch on Amazon.com for U.S. customers. Both are cosmetic products designed for different spot stages. A separate OTC Microdart Acne Patch with 2% salicylic acid is planned for October 2026 and carries its own Drug Facts labeling.
Issued by CLERIVY, a brand operated by GUHADA Co., Ltd. · Distributed via PR Newswire.
These links document third-party distribution of CLERIVY's August 25, 2026 U.S. launch announcement. The U.S. and global pages are syndicated copies of the company announcement, not independent product reviews or editorial endorsements. The Korean-language outlets published articles about the launch.
Syndicated company announcement ·
Syndicated company announcement ·
Syndicated company announcement ·
Syndicated company announcement ·
Syndicated company announcement ·
Korean-language launch article ·
구하다, 스킨케어 브랜드 ‘클레리비’ 미국 아마존 진출…OTC 패치는 10월 출시
Read CLERIVY launch coverage on Korea Daily (미주중앙일보) ↗Korean-language launch article ·
구하다, 자체 브랜드 트러블 패치 2종 미국 아마존 판매 개시
Read CLERIVY launch coverage on EToday (이투데이) ↗Korean-language launch article ·
‘검증된 성분’ 앞세웠다… 구하다, 자체 스킨케어 브랜드 미국 아마존 론칭
Read CLERIVY launch coverage on Fashionbiz (패션비즈) ↗Korean-language launch article ·
구하다, 美 트러블 케어 시장 공략…‘클레리비’ 아마존 론칭
Read CLERIVY launch coverage on MyDaily (마이데일리) ↗If you are comparing Korean pimple patches, start with the stage of the spot and the product classification. Choose the cosmetic Microdart Spot Patch for an early bump you can feel before it surfaces. Choose the cosmetic Hydrocolloid Pimple Patch for a surfaced spot on healthy, intact skin that you want to cover. The Microdart Acne Patch is a separate OTC drug for acne with its own Drug Facts label and is scheduled for October 2026.
Early bump · Cosmetic · Available now
A cosmetic two-step kit for an early bump you can feel before it surfaces. Each 13.5 mm patch has 16 water-soluble microdarts and is used with the included Blemish Clearing Pad. The formula features 7% niacinamide, 3% tranexamic acid, and a vitamin C derivative. Available in 6-, 12-, and 18-patch kits.
Surfaced spot · Cosmetic · Available now
A cosmetic hydrocolloid patch for covering a surfaced spot on healthy, intact skin. Available in 10 mm and 12 mm sizes, with 30-, 72-, and 96-count boxes. Apply to clean, completely dry skin and follow the on-pack direction: wear for 4–8 hours, or until the patch turns opaque. Contains less than 0.5% salicylic acid for cosmetic purposes only.
OTC monograph drug · Scheduled for October 2026
A separate OTC monograph drug for acne with 2% salicylic acid as its sole active ingredient. Four- and eight-patch packs are planned for U.S. release in October 2026. Follow its Drug Facts label; do not apply the cosmetic-patch directions to this product.
Compare CLERIVY hydrocolloid and microdart pimple patches by spot stage →
CLERIVY separates each patch by spot stage and product classification. The cosmetic Microdart Spot Patch is for an early bump, while the cosmetic Hydrocolloid Pimple Patch is for a surfaced spot on healthy, intact skin. The Microdart Acne Patch is a separate OTC monograph drug with its own Drug Facts labeling. FDA listing does not constitute FDA approval or endorsement of the product.
The Hydrocolloid Pimple Patch and Microdart Spot Patch each have two one-week use studies and a separate 24-hour primary skin irritation patch test. The two one-week Microdart Spot Patch studies evaluated the complete Blemish Clearing Pad and patch routine. The 24-hour tests evaluated each patch separately. These six studies do not apply to the Microdart Acne Patch.
Hydrocolloid Pimple Patch only
CUTIS Biomedical Research Center conducted a one-week sensitive-skin human use study with 23 participants (CBRC-E-260610-52). No assessed adverse skin reactions were observed.
Hydrocolloid Pimple Patch only
CUTIS Biomedical Research Center conducted a one-week non-comedogenic human use study with 22 participants (CBRC-E-260610-53). No assessed adverse skin reactions were observed.
Microdart Spot Patch only
CUTIS Biomedical Research Center conducted a one-week sensitive-skin study with 23 participants (CBRC-E-260611-54). No assessed adverse skin reactions were observed during the 1-week study.
Microdart Spot Patch only
CUTIS Biomedical Research Center conducted a one-week non-comedogenic and blemish-area study with 21 participants (CBRC-E-260611-55). No assessed adverse skin reactions were observed during the 1-week study.
Hydrocolloid Pimple Patch only
In a 24-hour primary skin irritation patch test of 31 adults (CBRC-I-260818-96-01), no irritation reactions were observed at the 1- or 24-hour assessments after removal; the mean skin reaction score was 0.00 under the report criteria.
Microdart Spot Patch only
In a 24-hour primary skin irritation patch test of 31 adults (CBRC-I-260818-96-02), no irritation reactions were observed at the 1- or 24-hour assessments after removal; the mean skin reaction score was 0.00 under the report criteria.
The two one-week Microdart Spot Patch studies evaluated the complete routine: Blemish Clearing Pad followed by Microdart Spot Patch. The separate 24-hour primary skin irritation patch tests excluded people with sensitive or hypersensitive skin. These short-term results do not mean non-irritating, hypoallergenic, or suitable for every skin type. The Hydrocolloid Pimple Patch and Microdart Spot Patch are cosmetic products; neither is intended to treat, prevent, or cure acne or any other medical condition.
Explore our brand story, compare patch formats, and find product testing, directions, and the separate OTC Drug Facts.
High-resolution originals, approved CLERIVY logo files, captions, and product fact checks are available to journalists through the Media Contact below.
CLERIVY is a Korean skincare brand bringing clarity to blemish care. We create hydrocolloid pimple patches for surfaced spots and microdart spot patches for early bumps—so each patch fits a different spot stage. Our name brings together CLEAR and VALIDITY through “I,” for Individual and Ingredients: individual skin needs, ingredients chosen with purpose, and product information made easier to understand.
CLERIVY organizes pimple patches by spot stage and product classification. Its cosmetic Microdart Spot Patch is for early bumps, its cosmetic Hydrocolloid Pimple Patch is for surfaced spots, and its Microdart Acne Patch is a separate OTC monograph drug with its own Drug Facts labeling.
CLERIVY
CLERIVY MICRODART ACNE (salicylic acid 2%) is listed with the U.S. Food and Drug Administration as an over-the-counter monograph drug under OTC Monograph M006, Topical Acne Drug Products. The 4-patch and 8-patch packs carry NDC 87934-111-04 and NDC 87934-111-08, respectively. The listing identifies GUHADA Co., Ltd. as the labeler. Its complete Drug Facts labeling is published by the U.S. National Library of Medicine under SPL Set ID 555e0963-025e-3731-e063-6394a90a679d.
Listing of a drug with FDA does not constitute FDA approval or endorsement of the product. CLERIVY Microdart Acne Patch is scheduled for U.S. release in October 2026.
CLERIVY Hydrocolloid Pimple Patch and CLERIVY Microdart Spot Patch are cosmetic products and are not drugs. Both cosmetic packages state: “This product contains less than 0.5% Salicylic Acid for cosmetic purposes only. It is not intended to treat, prevent, or cure acne or any other medical condition.”
Blemish Clearing Pads included with the Microdart Spot Patch are not intended for sanitizing or antiseptic use.
Last updated:
Be the first to hear about new product launches, exclusive sale access, and invites to community events.
Be the first to hear about new product launches, exclusive sale access, and invites to community events.
BRAND
BRAND
BRAND
© GUHADA Co., Ltd. 2026
© GUHADA Co., Ltd. 2026
